Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 18377662 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Bhattacharya R, et al. (2008) Src homology 2 (SH2) domain containing protein tyrosine phosphatase-1 (SHP-1) dephosphorylates VEGF Receptor-2 and attenuates endothelial DNA synthesis, but not migration*. J Mol Signal 3, 8 18377662
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

Y536-p - SHP-1 (human)
Orthologous residues
SHP‑1 (human): Y536‑p, SHP‑1 iso4 (human): Y536‑p, SHP‑1 (mouse): Y536‑p, SHP‑1 (rat): Y538‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced

Y951-p - VEGFR2 (human)
Orthologous residues
VEGFR2 (human): Y951‑p, VEGFR2 (mouse): Y949‑p, VEGFR2 (rat): Y947‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
siRNA VEGF SHP-1 (human) no effect upon treatment-induced increase
PP2 VEGF no effect upon treatment-induced increase
PP3 VEGF no effect upon treatment-induced increase

Y996-p - VEGFR2 (human)
Orthologous residues
VEGFR2 (human): Y996‑p, VEGFR2 (mouse): Y994‑p, VEGFR2 (rat): Y992‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE SHP-1 (human) siRNA inhibition of enzyme, phospho-antibody, pharmacological inhibitor of upstream enzyme, co-immunoprecipitation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
siRNA VEGF SHP-1 (human) augment treatment-induced increase
PP2 VEGF augment treatment-induced increase
PP3 VEGF no effect upon treatment-induced increase

Y1059-p - VEGFR2 (human)
Orthologous residues
VEGFR2 (human): Y1059‑p, VEGFR2 (mouse): Y1057‑p, VEGFR2 (rat): Y1055‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE SHP-1 (human) siRNA inhibition of enzyme, phospho-antibody, pharmacological inhibitor of upstream enzyme, co-immunoprecipitation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
siRNA VEGF SHP-1 (human) augment treatment-induced increase
PP2 VEGF augment treatment-induced increase
PP3 VEGF no effect upon treatment-induced increase

Y1175-p - VEGFR2 (human)
Orthologous residues
VEGFR2 (human): Y1175‑p, VEGFR2 (mouse): Y1173‑p, VEGFR2 (rat): Y1171‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE SHP-1 (human) siRNA inhibition of enzyme, phospho-antibody, pharmacological inhibitor of upstream enzyme, co-immunoprecipitation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
siRNA VEGF SHP-1 (human) augment treatment-induced increase
PP2 VEGF augment treatment-induced increase
PP3 VEGF no effect upon treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.